Clearmind Medicine is advancing CMND-100 in Alcohol Use Disorder. Discover why the non-hallucinogenic neuroplastogen market is gaining attention.
Hansa Biopharma’s imlifidase faces a decisive FDA year as Phase 3 transplant data test whether desensitization can unlock donor access.
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.
AI drug platforms need clinical proof. Passkey’s new CMO must show whether Locksmith-picked combinations can move faster into patients.
Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Cornerstone Robotics has cleared Europe’s MDR bar for Sentire. The real test is whether surgical robotics can scale beyond elite hospitals.
Find out how DMOS Orthopaedic Centers’ new workers’ comp portal could speed referrals, reduce delays and improve injury-care coordination.
Find out how Curia’s $4m Valladolid aseptic suite upgrade could strengthen sterile API manufacturing and Annex 1 readiness.
Find out how Resbiotic and Tiny Health’s at-home microbiome test could reshape consumer gut health, diagnostics and personalised wellness.